Prophylaxis in a Patch - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Prophylaxis in a Patch
New studies reveal the promise and feasibility of transdermal vaccine delivery.


Pharmaceutical Technology
Volume 35, Issue 8, pp. 14


Erik Greb
The growth in the biologics market has given the industry an extra incentive to find painless ways of administering vaccines. Recent animal studies indicate that the transdermal route could be a viable option.

Researchers from the Georgia Institute of Technology vaccinated mice against influenza using patches that contained dissolving microneedles. This administration method provided at least as much protection as traditional hypodermic injections, according to their July 2010 article in Nature Medicine.

A $10-million grant from the National Institutes of Health will enable the researchers, in cooperation with Emory University, to develop the patch further and conduct a Phase I clinical trial. The patch uses a dry form of the vaccine, and the team will study its stability to determine whether it can be stored without refrigeration.

Another goal of the study is to ensure that the patch is simple and reliable enough for any patient to use without assistance, says Mark Prausnitz, the project's principal investigator. If the study is successful, the patch eventually could become a more popular delivery device than autoinjectors.

Until recently, transdermal delivery had been restricted to small and lipophilic molecules. Projects such as Prausnitz's open the possibility that vaccines and other large-molecule drugs could be given effectively through the skin. Such easy and painless administration could have big benefits for public health. For needlephobes and drug-delivery scientists alike, the prospects are exciting.

Erik Greb is an associate editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here